These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 23337790

  • 1. Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor, on the growth of colon cancer cells.
    Zamri N, Masuda N, Oura F, Yajima Y, Nakada H, Fujita-Yamaguchi Y.
    Biosci Trends; 2012 Dec; 6(6):303-12. PubMed ID: 23337790
    [Abstract] [Full Text] [Related]

  • 2. Characterization of anti-Tn-antigen MLS128 binding proteins involved in inhibiting the growth of human colorectal cancer cells.
    Zamri N, Masuda N, Oura F, Kabayama K, Yajima Y, Nakada H, Yamamoto K, Fujita-Yamaguchi Y.
    Biosci Trends; 2013 Oct; 7(5):221-9. PubMed ID: 24241172
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of cancer cell growth by anti-Tn monoclonal antibody MLS128.
    Morita N, Yajima Y, Asanuma H, Nakada H, Fujita-Yamaguchi Y.
    Biosci Trends; 2009 Feb; 3(1):32-7. PubMed ID: 20103942
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells.
    Ohtani M, Numazaki M, Yajima Y, Fujita-Yamaguchi Y.
    Biosci Trends; 2009 Aug; 3(4):131-8. PubMed ID: 20103837
    [Abstract] [Full Text] [Related]

  • 5. Surface plasmon resonance and NMR analyses of anti Tn-antigen MLS128 monoclonal antibody binding to two or three consecutive Tn-antigen clusters.
    Matsumoto-Takasaki A, Hanashima S, Aoki A, Yuasa N, Ogawa H, Sato R, Kawakami H, Mizuno M, Nakada H, Yamaguchi Y, Fujita-Yamaguchi Y.
    J Biochem; 2012 Mar; 151(3):273-82. PubMed ID: 22161472
    [Abstract] [Full Text] [Related]

  • 6. MLS128 antibody-induced suppression of colon cancer cell growth is mediated by a desmocollin and a 110 kDa glycoprotein.
    Shuck SC, Hong T, Kalkum M, Igarashi R, Kajiya K, Termini J, Yamamoto K, Fujita-Yamaguchi Y.
    Biosci Trends; 2019 Jul 22; 13(3):216-224. PubMed ID: 31168022
    [Abstract] [Full Text] [Related]

  • 7. Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells.
    Zhang Y, Zhang Y.
    Cancer Invest; 2008 Jul 22; 26(3):230-6. PubMed ID: 18317963
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility to proteases of anti-Tn-antigen MLS128 binding glycoproteins expressed in human colon cancer cells.
    Oura F, Yajima Y, Nakata M, Taniue K, Akiyama T, Nakada H, Yamamoto K, Fujita-Yamaguchi Y.
    Biosci Trends; 2015 Feb 22; 9(1):49-55. PubMed ID: 25787909
    [Abstract] [Full Text] [Related]

  • 9. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.
    Cancer Res; 2003 Feb 01; 63(3):627-35. PubMed ID: 12566306
    [Abstract] [Full Text] [Related]

  • 10. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
    Kusada Y, Morizono T, Matsumoto-Takasaki A, Sakai K, Sato S, Asanuma H, Takayanagi A, Fujita-Yamaguchi Y.
    J Biochem; 2008 Jan 01; 143(1):9-19. PubMed ID: 17956902
    [Abstract] [Full Text] [Related]

  • 11. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D.
    Cancer Res; 2006 Feb 15; 66(4):2391-402. PubMed ID: 16489046
    [Abstract] [Full Text] [Related]

  • 12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 13. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.
    Cancer Res; 2003 Dec 15; 63(24):8912-21. PubMed ID: 14695208
    [Abstract] [Full Text] [Related]

  • 14. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.
    Cancer Res; 2001 Sep 15; 61(18):6747-54. PubMed ID: 11559546
    [Abstract] [Full Text] [Related]

  • 15. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM.
    Ann Surg Oncol; 2007 Oct 15; 14(10):2838-46. PubMed ID: 17653802
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation.
    Jackson-Booth PG, Terry C, Lackey B, Lopaczynska M, Nissley P.
    Horm Metab Res; 2003 Oct 15; 35(11-12):850-6. PubMed ID: 14710368
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M.
    Cancer Res; 2003 Oct 15; 63(20):6726-34. PubMed ID: 14583467
    [Abstract] [Full Text] [Related]

  • 19. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.
    Lung Cancer; 2008 May 15; 60(2):166-74. PubMed ID: 18006183
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
    Ii M, Li H, Adachi Y, Yamamoto H, Ohashi H, Taniguchi H, Arimura Y, Carbone DP, Imai K, Shinomura Y.
    Clin Cancer Res; 2011 Aug 01; 17(15):5048-59. PubMed ID: 21642381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.